GelStat Corporation (GSAC) Stock

About GelStat Corporation

GelStat Corporation operates as a consumer healthcare enterprise, specializing in the innovation, formulation, and commercialization of over-the-counter (OTC) and other non-prescription health solutions. Its diverse product portfolio addresses various common health concerns, featuring: GelStat Migraine, a patented remedy targeting migraine headache pain; Chews 2 Lose, an appetite-controlling gum designed to assist with weight management; All Natural Speed, formulated as an energy booster; and GelStat Sleep, intended to alleviate sleep disturbances and their related symptoms. GelStat distributes its solutions through a comprehensive network, reaching retailers, wholesalers, specialized distributors, and catalog merchandisers. This is achieved both through direct sales and via independent sales brokerage agreements. The corporation maintains its principal office in Palm City, Florida.

GelStat Corporation (GSAC) stock trades at $0.00 with a market capitalization of $185394. The stock is valued at a price-to-earnings (P/E) ratio of -4.57, price-to-book of -0.78, price-to-sales of 1.28. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, GelStat Corporation generates a return on equity (ROE) of 0.00%, return on capital employed of 35.96%, an operating margin of -87.01%, a net profit margin of -77.96%.

Official website: www.gelstat.com